Profile data is unavailable for this security.
About the company
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in the development of a programmable epigenomic mRNA medicine to treat or cure a broad range of diseases. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The Company designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.
- Revenue in USD (TTM)8.10m
- Net income in USD-73.09m
- Incorporated2016
- Employees93.00
- LocationOmega Therapeutics Inc140 First Street, Suite 501CAMBRIDGE 02141United StatesUSA
- Phone+1 (617) 949-4360
- Fax+1 (302) 655-5049
- Websitehttps://omegatherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Iterum Therapeutics PLC | 0.00 | -30.55m | 40.19m | 14.00 | -- | -- | -- | -- | -2.00 | -2.00 | 0.00 | -0.5068 | 0.00 | -- | -- | 0.00 | -109.80 | -118.12 | -297.32 | -199.23 | -- | -- | -- | -890,554.10 | -- | -7.38 | 2.05 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| Xilio Therapeutics Inc | 4.62m | -62.80m | 40.44m | 73.00 | -- | 1.93 | -- | 8.75 | -1.72 | -1.72 | 0.1046 | 0.4771 | 0.0606 | -- | -- | 63,287.67 | -82.36 | -- | -128.76 | -- | -- | -- | -1,359.37 | -- | -- | -320.73 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| Rallybio Corp | 598.00k | -66.97m | 41.01m | 25.00 | -- | 0.5792 | -- | 68.59 | -1.59 | -1.59 | 0.0141 | 1.71 | 0.0056 | -- | -- | 13,906.98 | -63.12 | -- | -68.83 | -- | -- | -- | -11,199.50 | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -33.38m | 41.47m | 15.00 | -- | -- | -- | -- | -1.12 | -1.12 | 0.00 | -0.2985 | 0.00 | -- | -- | 0.00 | -512.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| Gain Therapeutics Inc | 0.00 | -21.37m | 42.06m | 29.00 | -- | 4.72 | -- | -- | -1.13 | -1.13 | 0.00 | 0.3432 | 0.00 | -- | -- | 0.00 | -150.14 | -- | -236.03 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0526 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| Vyne Therapeutics Inc | 493.00k | -33.95m | 42.78m | 10.00 | -- | 0.6733 | -- | 86.77 | -0.8493 | -0.8509 | 0.0124 | 4.31 | 0.0103 | -- | -- | 49,300.00 | -71.12 | -108.41 | -88.91 | -138.57 | -- | -- | -6,885.40 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Omega Therapeutics Inc | 8.10m | -73.09m | 42.80m | 93.00 | -- | 3.71 | -- | 5.29 | -1.33 | -1.33 | 0.1468 | 0.2093 | 0.0437 | -- | 18.34 | 87,043.01 | -39.45 | -- | -45.75 | -- | -- | -- | -902.93 | -- | -- | -- | 0.5745 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Serina Therapeutics Inc | 126.00k | -11.86m | 43.52m | 4.00 | -- | -- | -- | 345.39 | -4.58 | -4.58 | 0.0184 | -1.55 | 0.0128 | -- | 2.96 | 31,500.00 | -121.28 | -194.46 | -771.07 | -- | 43.65 | 85.80 | -9,454.76 | -2,347.36 | -- | -- | -- | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
| vTv Therapeutics Inc | 1.00m | -18.31m | 44.64m | 16.00 | -- | 3.15 | -- | 44.64 | -4.42 | -4.42 | 0.2194 | 4.71 | 0.0344 | -- | 8.26 | 62,500.00 | -78.19 | -111.84 | -163.60 | -- | -- | -- | -2,270.90 | -680.94 | -- | -- | 0.00 | -- | -100.00 | -- | -5.67 | -- | -- | -- |
| IO Biotech Inc | 0.00 | -90.34m | 44.93m | 68.00 | -- | 0.6192 | -- | -- | -1.37 | -1.37 | 0.00 | 1.10 | 0.00 | -- | -- | 0.00 | -68.83 | -- | -77.39 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| OncoCyte Corp | 709.00k | -43.61m | 44.95m | 43.00 | -- | 3.68 | -- | 63.40 | -4.43 | -4.43 | 0.0658 | 0.7261 | 0.0093 | -- | 0.6781 | 16,488.37 | -56.84 | -35.11 | -64.07 | -39.71 | -16.22 | -- | -6,085.19 | -2,373.36 | 0.5018 | -153.67 | 0.0948 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
| Actinium Pharmaceuticals Inc | 81.00k | -40.92m | 45.86m | 49.00 | -- | 1.20 | -- | 566.15 | -1.40 | -1.40 | 0.0028 | 1.22 | 0.001 | -- | -- | 1,653.06 | -47.84 | -46.98 | -52.92 | -52.71 | -- | -- | -50,512.34 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| Calcimedica Inc | 0.00 | -13.59m | 46.51m | 14.00 | -- | 4.11 | -- | -- | -1.57 | -1.57 | 0.00 | 0.8391 | 0.00 | -- | -- | 0.00 | -84.77 | -63.99 | -110.52 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
Data as of Nov 22 2024. Currency figures normalised to Omega Therapeutics Inc's reporting currency: US Dollar USD
21.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 6.06m | 10.99% |
| State of Wisconsin Investment Boardas of 30 Sep 2024 | 1.86m | 3.37% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.11m | 2.01% |
| 683 Capital Management LLCas of 30 Sep 2024 | 600.00k | 1.09% |
| Millennium Management LLCas of 30 Sep 2024 | 535.62k | 0.97% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 474.60k | 0.86% |
| Point72 Asset Management LPas of 30 Sep 2024 | 469.90k | 0.85% |
| Platinum Investment Management Ltd.as of 30 Sep 2024 | 346.35k | 0.63% |
| Michigan Department of Treasury (Investment Management)as of 30 Sep 2024 | 314.12k | 0.57% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 266.62k | 0.48% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
